Previous Close | 4.82 |
Open | 4.95 |
Bid | 4.75 x 900 |
Ask | 5.30 x 1400 |
Day's Range | 4.70 - 5.07 |
52 Week Range | 3.83 - 19.46 |
Volume | |
Avg. Volume | 850,954 |
Market Cap | 199.488M |
Beta (5Y Monthly) | 1.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.11 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 20, 2017 |
1y Target Est | 26.43 |
The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will give an oral presentation at the 5th Global NASH Congress on May 26-27, 2022, in London, UK. His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris
GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate at the following investor conferences in May 2022: H.C. Wainwright Global Investment ConferenceTuesday, May 24, 20227:00 am Eastern TimeThe session will be webcast and can be accessed by visiting the Events section of the Altimmune website. B. Riley Securities Institutional Investor Conference